Metachromatic Leukodystrophy (MLD) Cell Models for Research

Metachromatic leukodystrophy (MLD) is a rare autosomal recessive lysosomal storage disease caused by deficient activity of arylsulfatase A (ARSA), leading to accumulation of sulfatides in the nervous system. The global incidence is estimated at 1 in 40,000 to 1 in 160,000 live births (WHO, 2023). The disease presents in three main forms: late-infantile (most common, onset before 2 years), juvenile (onset 3-16 years), and adult (onset after 16 years). Prognosis is poor; most children with late-infantile MLD do not survive beyond early adolescence. There is no cure, and current treatments (hematopoietic stem cell transplantation, gene therapy) are limited by disease stage. The disease burden is significant due to progressive neurodegeneration, loss of motor and cognitive functions, and high caregiver burden. Research is critical to understand disease mechanisms and develop effective therapies.

MLD is an ideal model for studying lysosomal dysfunction, neurodegeneration, and demyelination. The monogenic nature (ARSA mutations) simplifies genetic modeling. Subtypes with varying onset and severity provide a spectrum for genotype-phenotype studies. Public datasets, such as those from the NCI and NCBI, include gene expression and mutation data. Open questions include the role of sulfatide accumulation in oligodendrocyte toxicity, the contribution of neuroinflammation, and the identification of modifiers. Gene-edited cell models enable precise manipulation of ARSA and related genes to dissect pathways and test therapeutic interventions.

The primary pathogenic pathway in MLD involves the deficiency of arylsulfatase A (ARSA), which leads to accumulation of sulfatides (galactosylceramide-3-sulfate) in lysosomes. This accumulation triggers a cascade of events:

1. Lysosomal storage of sulfatides in oligodendrocytes, Schwann cells, and neurons.

2. Activation of inflammatory responses, including microglial activation and astrogliosis.

3. Oxidative stress and mitochondrial dysfunction.

4. Apoptosis of oligodendrocytes, leading to demyelination.

5. Axonal degeneration and neuronal loss.

Additionally, secondary alterations in lipid metabolism, such as altered ganglioside composition, contribute to membrane instability and impaired cell signaling.

Data from ClinVar and NCBI Gene. The most common ARSA mutations include c.459+1G>A (splice site) and p.P426L (missense), which are associated with late-infantile and juvenile forms, respectively.

Sulfatide accumulation disrupts multiple signaling pathways:

• • Sphingolipid signaling: Altered ceramide and sphingosine-1-phosphate levels affect cell survival and proliferation.
• • MAPK/ERK pathway: Chronic stress activates ERK, leading to aberrant cell cycle regulation.
• • PI3K/AKT pathway: Impaired AKT signaling contributes to oligodendrocyte apoptosis.
• • Inflammatory signaling: Activation of NF-κB and JAK/STAT pathways in microglia and astrocytes promotes neuroinflammation.
• • Autophagy-lysosomal pathway: Impaired autophagy due to lysosomal dysfunction exacerbates protein aggregation and cell death.

Organoid models, such as cerebral organoids derived from MLD patient iPSCs, recapitulate 3D brain architecture and allow study of cell-cell interactions and myelination. They are valuable for testing therapeutic agents and gene editing strategies.

• • ARSA knockout mouse: The most widely used model; exhibits progressive demyelination and motor deficits.
• • Saposin B knockout mouse: Models PSAP mutations; shows similar pathology.
• • Induced models: Intracerebral injection of sulfatide or antisense oligonucleotides to knock down ARSA in wild-type mice.
• • Patient-derived xenograft (PDX): Not commonly used for MLD due to the non-oncological nature, but iPSC-derived cells can be transplanted into immunodeficient mice to study human cell behavior.

CRISPR-Cas9 technology enables the generation of isogenic cell lines with precise ARSA knockouts or knock-in of patient-specific mutations. These models are essential for studying genotype-phenotype correlations and for drug screening. For example, an ARSA knockout SH-SY5Y line can be used to assess sulfatide accumulation and test enzyme replacement or gene therapy candidates. Similarly, a knock-in line carrying the common p.P426L mutation allows modeling of the juvenile form. Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent, validated models. These are available from commercial sources without naming specific companies.

Gene-edited cell models are used to validate the function of ARSA and other genes in MLD pathogenesis. For example, ARSA knockout lines confirm the role of ARSA in sulfatide clearance. Knock-in of specific mutations allows assessment of residual enzyme activity and cellular phenotype. CRISPR screens can identify genetic modifiers that rescue the phenotype, providing novel therapeutic targets.

Isogenic pairs (wild-type vs. ARSA knockout) are used in high-throughput screening to identify compounds that reduce sulfatide accumulation or protect against cytotoxicity. These models also enable testing of drug resistance mechanisms, such as upregulation of alternative sulfatide degradation pathways. Resistance to enzyme replacement therapy can be modeled by prolonged exposure to recombinant ARSA.

CRISPR synthetic lethality screens can identify genes that, when silenced, are lethal only in ARSA-deficient cells. Such genes may serve as biomarkers for disease progression or as targets for therapeutic intervention. Additionally, secretome analysis of gene-edited cells can identify soluble biomarkers for MLD.